[Skip to Content]
[Skip to Content Landing]
May 24/31, 2000

AIDS-Related Opportunistic Illness and Potent Antiretroviral Therapy—Reply

Author Affiliations

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;283(20):2653-2654. doi:10.1001/jama.283.20.2653

In Reply: Dr Engels and colleagues argue that in our study of the incidence and risk factors of acquired immunodeficiency syndrome (AIDS)–related opportunistic illnesses after the initiation of potent antiretroviral therapy, we may have underestimated or overestimated the effectiveness of antiretroviral therapy. Our aim was not to estimate the effectiveness of antiretroviral combination therapy, which has been conclusively demonstrated in randomized controlled trials1 and prospective cohort studies.24 Rather, we set out to examine incidence trends and risk factors for individual opportunistic illnesses in a stable cohort of HIV-infected adults, covering defined periods before and immediately after starting potent therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview